Table 1.
Characteristics and outcomes of studies included in the review
| Ref. | Nr of pts | Mean age (range) |
Prescription dose / number of fraction
|
CR rate (%) | Local control (%) | R0 rate (%) | Sphincter preservation rate (%) |
Toxicity (%)
|
Surgery complications (%, any grade) | ||
|
Boost dose
|
Prophylactic dose
|
G2
|
G3 OR >
|
||||||||
| Alongi et al[37], 2016 | 40 | 69 (47-83) | 60/30 | 54/30 | 17.5 | 100 | 100.0 | 92.5 | GI 15, GU 12.5 | 0 | 10.0 |
| Couwenberg et al[38], 2020 | 51 | 64.5 (55-69) | 50/25, + 15/5 | 50/25 | 35.9 | - | - | 56.3 | GI 20, GU 7.8, Sk 9.4 | GI 9.3, GU 1.6 | 26.4 |
| Bertocchi et al[39], 2020 | 31 | 68.7 (47-81) | 60/30 | 50.4/30 | 22.6 | - | 100.0 | 93.5 | GI 16.1, GU 19.3 | 0 | 41.9 |
| Engels et al[40], 2014 | 57 | 69 (32-85) | 55.2/23 | 46/23 | - | 97 | - | - | GI 12.2, GU 12.2, Sk 36.8 | 14 | -- |
| Hernando-Requejo et al[41], 2014 | 74 | 61.7 (33-80) | 57.6/23 | 46/23 | 30.6 | 100 | 97.2 | 77.7 | GI 28.4, GU 9.5, Sk 21.6 | GI 9.5, GU 5.4, Sk 2.7 | 25.7 |
| Zhu et al[42], 2014 | 78 | 54 (30-76) | 55/25 | 50/25 | 23.7 | 85.4 | 100.0 | 36.8 | GI 14.1, Sk 20.5 | GI 10.3, Sk 17.9 | 17.1 |
| Wang et al[43], 2019 | 60 | 56 (22-75) | 55/25 | 50/25 | 28.1 | 90.6 | 100.0 | 38.6 | / | 25 | 24.6 |
| Lima et al[44], 2019 | 11 | 45.9 (28-59) | 54/30 | 28.5 | - | - | - | 40 | 20 | - | |
| Jankarashvili et al[45], 2019 | 22 | 59 (36-84) | 57.5/23 | 46/23 | 59.1 | - | 100.0 | - | GI 40.9, GU 22.7, Sk 45.5 | GI 0GU 13.6, Sk 9.1 | - |
| Parikh et al[46], 2019 | 44 | 67 (47-84) | 55.8/31 | 40.9 | 93.2 | - | 100.0 | 6.8 | 0 | 43.0 | |
| Passoni et al[47], 2013 | 25 | 59 (37-77) | 27.6/12 + 18/6 | 41.4/18 | 30.0 | 100 | 96.0 | 87.0 | - | GI 12 | 26.0 |
| Picardi et al[48], 2016 | 18 | 62 (39-79) | 57.5/25 | 45/25 | 25.0 | 100 (1y), 68.6 (3y), 68.6 (5y) | 100.0 | 62.5 | - | 44.4 | - |
| Spatola et al[49], 2019 | 62 | 61.5 (36-84) | 45/25 + 9/6 | 45/25 | 19.0 | 96.5 | 100.0 | 85.0 | - | GI 10, GU 0, Sk 3 | 5.0 |
| Liu et al[50], 2020 | 85 | 80 (75-85) | 55/25 | 45-50/25 | 21.4 | 83.9 | 78.6 | - | GI 5.2, GU 1.8 | 12.5 | |
| Yamashita et al[51], 2017 | 60 | 66 (44-88) | 55/25 | 45/25 | 17.0 | 90 | 100.0 | 88.0 | GU 49 | 0 | 3.0 |
| Yang et al[52], 2019 | 26 | 55 (18-75) | 58.75/25 | 50/25 | 32.0 | 100.0 | 60.0 | GI 30.8, Sk 7.7 | Sk 7.7 | 8.0 | |
| Alsuhaibani et al[53], 2018 | 79 | 59.7 (28–102) | 55/25 | 45 | 20.0 | - | 100.0 | 72 ? | - | 0 | - |
| Chiloiro et al[54], 2019 | 22 | 64 (41–86) | 55/25 | 45 | 27.3 | - | 100.0 | 89.5 | GU 0, GI 40 | GI 22.7 | - |
| Lupattelli et al[55], 2016 | 60 | 64 (29–84) | 57-55-54/25 | 45 | 27.8 | - | 96.0 | 85.7 | - | 10.5 | 18.1 |
| Tey et al[56], 2017 | 20 | - | 55/25 | 45 | 35.0 | 100 | 95.0 | 85.0 | 0 | 5 | 0.0 |
| Zhao et al[57], 2017 | 141 | 59 (50–67) | 55/25 | 45-30 | 22.7 | 95.5 | 97.9 | 80.0 | - | GI 7.8 | 10.6 |